BIA-Brukerstyrt innovasjonsarena
Expanding drug pipeline in Avexxin - adopting new chemistry
Since incorporation in 2005, Avexxin has had an ongoing development program on its lead compound, AVX001, against psoriasis, and the company is now at the brink of completing pre-clinical tox studies, which is prerequisite to enter into human trials. In a ccordance with Avexxin?s therapeutic stra...